A new artificial intelligence (AI) tool has demonstrated the ability to significantly enhance the diagnosis of Sjögren’s disease by rapidly and accurately analyzing tissue samples, according to a multicenter European study. The AI system achieved an accuracy of more than 87% in classifying the focus score, which is the…
Read more
The severity of fatigue experienced by people with Sjögren’s disease affects their pain severity, and also has an impact on the effect of external factors, such as weather changes and loud noises, that can amplify a patient’s pain. That’s according to the findings of a single-center study in Italy,…
Two global Phase 3 clinical trials are now testing dazodalibep, Amgen’s experimental therapy for Sjögren’s disease, in two groups of adults. One of the studies is still recruiting participants. One of the trials, called HZNP-DAZ-301 (NCT06104124), has completed enrollment of 651 people with moderate-to-severe systemic (body-wide) Sjögren’s…
People with Sjögren’s disease who received the experimental therapy ianalumab (VAY736) in Phase 3 clinical trials reported greater reductions in disease activity than those given a placebo within two months of starting treatment. That’s according to new data ianalumab’s developer, Novartis, shared at the American College of Rheumatology…
Get regular updates to your inbox.
